Janus Henderson Group PLC Sells 35,200 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Janus Henderson Group PLC decreased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 36,543 shares of the biopharmaceutical company's stock after selling 35,200 shares during the period. Janus Henderson Group PLC's holdings in Ultragenyx Pharmaceutical were worth $2,028,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $653,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 15.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 7,359 shares of the biopharmaceutical company's stock worth $302,000 after purchasing an additional 975 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 47.9% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 73,289 shares of the biopharmaceutical company's stock worth $3,012,000 after purchasing an additional 23,752 shares during the period. EFG Asset Management North America Corp. boosted its stake in Ultragenyx Pharmaceutical by 7.5% during the second quarter. EFG Asset Management North America Corp. now owns 125,561 shares of the biopharmaceutical company's stock valued at $5,161,000 after buying an additional 8,725 shares during the period. Finally, UMB Bank n.a. grew its position in Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 352 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on RARE shares. HC Wainwright raised their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, November 21st. Cantor Fitzgerald restated an "overweight" rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $87.46.

Ultragenyx Pharmaceutical Stock Performance

RARE traded down $1.11 on Friday, hitting $45.78. 794,192 shares of the company were exchanged, compared to its average volume of 772,828. The firm has a fifty day simple moving average of $50.47 and a two-hundred day simple moving average of $49.08. The stock has a market capitalization of $4.23 billion, a PE ratio of -7.08 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts' expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business's revenue was up 42.3% on a year-over-year basis. During the same quarter last year, the business earned ($2.23) earnings per share. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current year.

Insider Activity

In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.